Last reviewed · How we verify

NCT07237542: RIC-END

Effect of Remote Ischemic Preconditioning on Early Neurological Deterioration in Acute Perforating Artery Infarction

Recruiting now NA Last updated 3 February 2026
What this trial tests

NA trial testing remote ischemic preconditioning in Ischemic Stroke in 910 participants. Currently enrolling.

Timeline
11 December 2025
Primary endpoint
20 November 2027
20 November 2027

Quick facts

Lead sponsorJinling Hospital, China
PhaseNA
StatusRecruiting now
Study typeINTERVENTIONAL
Allocationrandomized
Designparallel
Maskingnone
Primary purposetreatment
Enrollment910
Start date11 December 2025
Primary completion20 November 2027
Estimated completion20 November 2027
Sites1 location across China

Drugs / interventions tested

Conditions studied

Sponsor

Jinling Hospital, China

Who can join

18 and older, any sex, with Ischemic Stroke or Remote Ischaemic Preconditioning. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This study aims to conduct a prospective, randomized, double-blind, multicenter, parallel-controlled, group-sequential trialto scientifically evaluate the safety and efficacy of remote ischemic preconditioning (RIC) in preventing early neurological deterioration (END) in patients with acute perforating artery infarction (PAI).

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other trials of remote ischemic preconditioning

Trials testing the same drug.

Other recruiting trials for Ischemic Stroke

Currently open trials in the same condition.

Other Jinling Hospital, China trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT07237542.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing